A Screening Test for HLA-B∗15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events

• Main Authors: Hua Fang (Author), Xiequn Xu (Author), Kulvinder Kaur (Author), Matthew Dedek (Author), Guang-dan Zhu (Author), Bae J. Riley (Author), Frank G. Espin (Author), Andria L. Del Tredici (Author), Tanya A. Moreno (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose:HLA-B∗15:02 is strongly associated with life-threatening severe skin hypersensitivity reactions in patients treated with carbamazepine (CBZ) and structurally related medications. FDA-approved labeling recommends HLA-B∗15:02 screening before CBZ therapy in patients of Asian ancestry. In this...